PURE Bioscience and Therapeutics, Inc. Expand Silver Dihydrogen Citrate Pharmaceutical Product Development Initiative (PR Newswire via Yahoo! Finance)
PURE Bioscience announced today the expansion of its joint development initiative with Therapeutics, Inc. to include development of PURE's silver dihydrogen citrate broad-spectrum antimicrobial as an active pharmaceutical ingredient in products for treatment of dermatophytoses such as Tinea pedis , onychomycosis , among others, as well as development of antimicrobial skin wash products,

Critical Therapeutics on Target to Submit NDA for Zileuton Controlled-Release Tablets in Third Quarter 2006 (Business Wire via Yahoo! Finance)
LEXINGTON, Mass.----May 2, 2006--Critical Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has accepted the Company's proposal to submit the New Drug Application for its controlled-release formulation of zileuton with six months of primary and accelerated stability data and provide additional stability data during the review period without impacting the action date